Skip to main content
. 2019 May 28;71(7):1101–1111. doi: 10.1002/art.40866

Figure 2.

Figure 2

Proportion of patients achieving A, major improvement in the Ankylosing Spondylitis Disease Activity Score (ASDAS‐MI) and B, 40% improvement in disease activity according to the Assessment of SpondyloArthritis international Society criteria (ASAS40) by week 52. P < 0.0001 for certolizumab pegol (CZP) versus placebo (PBO) at week 12 and week 52 for both ASDAS‐MI and ASAS40. NBBM = nonbiologic background medication.